Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation

Published:2003-05-28 Issue:11 Volume:31 Page:1023-1025
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Gruhn B,Meerbach A,Häfer R,Zell R,Wutzler P,Zintl F

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1704061.pdf

Reference10 articles.

1. Curtis RE, Travis L, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208–2216.

2. Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11: 113–116.

3. Meerbach A, Gruhn B, Egerer R et al. Semiquantitative PCR analysis of Epstein–Barr virus DNA in clinical samples of patients with EBV-associated diseases. J Med Virol 2001; 65: 348–357.

4. Gruhn B, Hongeng S, Yi H et al. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998; 12: 675–581.

5. Yang J, Tao Q, Flinn IW et al. Characterization of Epstein–Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055–4063.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Rituximab for persistent EBV DNAemia, and Its effect on donor‐specific antibody development in pediatric renal transplant recipients: A case series;Pediatric Transplantation;2021-08-21

2. Prevention of Epstein-Barr Virus Infection and PTLD following SOT;Post-Transplant Lymphoproliferative Disorders;2021

3. Stem Cell Transplantation: Infection Risk by Transplant Type and Emerging Trends in Infection Management;Emerging Transplant Infections;2021

4. Reducing infectious complications after allogeneic stem cell transplant;Expert Review of Hematology;2020-11-01

5. Stem Cell Transplantation: Infection Risk by Transplant Type and Emerging Trends in Infection Management;Emerging Transplant Infections;2020